Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $41.25 Average PT from Analysts

Posted by Francis Steltz on Sep 4th, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $41.25.

AGIO has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Royal Bank Of Canada boosted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Citigroup boosted their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st.

Check Out Our Latest Research Report on AGIO

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the transaction, the insider owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth about $239,582,000. California State Teachers Retirement System increased its holdings in shares of Agios Pharmaceuticals by 3,515.3% in the second quarter. California State Teachers Retirement System now owns 2,478,800 shares of the biopharmaceutical company’s stock worth $91,988,000 after acquiring an additional 2,410,236 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after acquiring an additional 2,049,287 shares in the last quarter. MPM Bioimpact LLC bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $35,478,000. Finally, ADAR1 Capital Management LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth $47,800,000.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $33.13 on Friday. The firm’s 50-day moving average is $35.73 and its 200-day moving average is $31.83. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -4.73 and a beta of 0.60. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The firm had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Equities analysts predict that Agios Pharmaceuticals will post -5.82 EPS for the current year.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.